
https://www.science.org/content/blog-post/pains-x-ray
# PAINs by X‑Ray (February 2018)

## 1. Summary

The article discusses "pan-assay interference compounds" (PAINS)—chemical structures known to produce frequent false positives in drug screening assays—and examines a new paper that analyzed these motifs in X‑ray crystallographic data from the Protein Data Bank (PDB). The study found over 2,700 structures involving PAINS ligands, representing about 1,100 distinct molecules, with evidence of binding promiscuity and some cases of reactive groups forming covalent adducts with proteins. However, many structures showed "normal" binding interactions without the problematic parts of the molecule engaging the protein. The author argues for a nuanced "yellow caution light" approach: neither automatically discarding all PAINS-motif compounds (since some have led to approved drugs) nor ignoring the risks, but rather applying extra scrutiny to evaluate assay-specific liabilities and having strong justification before pursuing such chemical matter.

## 2. History

After 2018, PAINS filters became a routine, early-stage component of virtual and experimental screening workflows in drug discovery. Software vendors, screening libraries, and academic platforms widely integrated PAINS filters as a default pre‑filtering step to de-prioritize or flag compounds likely to be frequent hitters or assay artifacts. Public repositories (e.g., ChEMBL, PubChem) and cheminformatics toolkits (RDKit, MOE, Schrödinger, ChemAxon) routinely provide or enable PAINS alerts.

Concrete impact evolved along several lines:
- **Tooling and databases**: The original PAINS substructure definitions (Baell and Holloway, 2010) were extended and curated; multiple vendors began offering PAINS filters and "clean" screening libraries explicitly marketed as PAINS‑filtered. Papers documented large-scale retrospective analyses of HTS and biochemical/ biophysical confirmatory data, generally supporting that flagged motifs produce false positives at higher rates.
- **Yield and downstream validation**: In screening campaigns, applying PAINS filters reduced hit-list sizes and helped avoid wasting resources on compounds that proved to be aggregators, redox-cyclers, fluorescent interferers, or promiscuous covalent modifiers. Best practices coalesced around orthogonal, biophysical validation (e.g., NMR, SPR, native mass spectrometry, orthogonal assay formats) before investing in PAINS-containing series.
- **Clinical outcomes and target/pathway context**: The industry did not abandon PAINS motifs universally, but pursued them only with clear justification and robust counter-screens. Some approved drugs (e.g., certain kinase inhibitors and antibacterials) contain substructures that trigger PAINS alerts; the key difference was rigorous target-engagement evidence and clinical validation. Conversely, programs advancing PAINS-rich candidates without sufficient validation often faced later-stage failures due to off-target effects, safety liabilities, or inability to confirm mechanism.
- **Public/crowdsourced data and policy influence**: Consortia, journals, and funding bodies increasingly requested or mandated PAINS-aware reporting and data deposition; some grant reviews and publication guidelines asked authors to address whether PAINS motifs were considered. This nudged labs toward more stringent hit triage.

Overall, the 2018 perspective—that PAINS are a "yellow caution light" requiring careful, context-aware evaluation rather than an automatic disqualifier—became the dominant industry stance. Widespread adoption improved the efficiency of hit-to-lead pipelines and reduced wasted effort on artifactual "hits."

## 3. Predictions

- **Implicit prediction**: Medicinal chemists will continue wrestling with PAINS as both a useful triage tool and a source of frustration, and that binary "toss vs. proceed" attitudes will soften into nuanced, risk-based decision-making.
  - **Outcome**: Largely correct. The "yellow caution light" framework prevailed. Labs typically treat PAINS as risk signals requiring orthogonal biophysical confirmation and clear rationale if kept, rather than as outright prohibitions. Computational filters are standard; teams now focus more on assay mechanism-specific interference (e.g., fluorescence, aggregation) and early biophysical de‑risking.
- **Implicit prediction**: More marketed drugs contain PAINS substructures than acknowledged, and context matters; not every flagged motif is a liability.
  - **Outcome**: True, but well-understood. Approved drugs with PAINS-like motifs exist (e.g., some dyes, kinase inhibitors, metal chelators), but they succeeded because of strong on-target engagement and acceptable safety profiles. The field now generally accepts that "PAINS" is a risk flag for screening artifacts and promiscuity, not a dispositive rule for all chemical matter in all contexts.
- **Implicit prediction**: Ignoring PAINS liabilities and proceeding "as if everything is going to be fine" would invite avoidable failures.
  - **Outcome**: Confirmed by practice. Projects that advance PAINS-rich molecules without rigorous mechanistic and biophysical validation frequently encounter time and cost overruns, off-target effects, and late-stage derisking issues. Best practice now combines in silico PAINS filters with functional, biophysical, and often cellular counter-screens.

## 4. Interest

Rating: **5/10**  
This piece reinforced a pragmatic, context-aware view of PAINS filters at a time when opinions were polarized. It provided a balanced synthesis as the field matured, but did not introduce fundamentally new concepts or change established practice.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20180213-pains-x-ray.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_